Mallinckrodt‘s (NYSE: MNK) Stratatech today received FDA approval for its StrataGraft for treating adult patients with thermal burns. The Bedminister, N.J.-based company designed StrataGraft to treat thermal burns that have intact dermal elements, or remaining deep skin layers, for which surgical intervention is clinically indicated. “Serious burns can be an incredibly difficult injury to treat and can […]
Mallinckrodt
Mallinckrodt shares fall following loss in patent dispute
Shares in Mallinckrodt Hospital Products (NYSE: MNK) have fallen 19% since a federal appeals court ruled on Tuesday that industrial gas company Praxair did not infringe its patents for a nitric oxide (iNO) delivery system. Nitric oxide gas has long been used to treat infants experiencing hypoxic respiratory failure and Mallinckrodt is the exclusive U.S. supplier […]
BARDA adds $26m to Stratatech’s StrataGraft development deal
Mallinckrodt‘s (NYSE: MNK) Stratatech has won an additional $26 million in Project BioShield funding from the the U.S. Biomedical Advanced Research and Development Authority to support pediatric studies of its StrataGraft engineered skin tissue. The funding will support continued development of the StrataGraft as a potential medical countermeasure for large-scale burn incidents, U.K.-based Mallinckrodt said. BARDA previously supplied […]
Motus GI taps Moran as CEO | Personnel Moves – September 25, 2018
Motus GI said today that it named Timothy Moran as its new chief executive officer, effective October 1, replacing former CEO Mark Pomeranz who will assume the role of president and COO. Moran has previously served ConvaTec‘s (LON:CTEC) Americas president and helped lead the company through its initial public offering in 2016. Prior to ConvaTec, Moran spent […]
Zimmer Biomet picks ex-Covidien exec Lannum for IR chief | Personnel Moves – March 20, 2018
Zimmer Biomet (NYSE:ZBH) said yesterday it tapped former Covidien investor relations head Coleman Lannum as its investor relations senior VP, reporting directly to prez & CEO Bryan Hanson. Lannum has more than 15 years in investor relations, having held positions with Mallinckrodt Pharmaceuticals (NYSE:MNK), Covidien and Tyco Healthcare. During his time with Covidien, Lannum oversaw the company’s initial […]
Baxter closes $153m hemostat, sealant asset buy from Mallinckrodt
Baxter (NYSE:BAX) said today that it closed the $153 million acquisition of hemostat and sealant assets from Mallinckrodt Pharmaceuticals (NYSE:MNK). Baxter announced in January its plan to acquire the stand-alone recombinant thrombin Recothrom and Preveleak surgical sealant for vascular reconstruction. “We are excited to add both Recothrom and Preveleak to our portfolio of hemostats and sealants to offer […]
Baxter buys Mallinckrodt’s Recothrom, Preveleak sealants for $153m
Baxter (NYSE:BAX) said today it inked an agreement with Mallinckrodt Pharmaceuticals (NYSE:MNK) to acquire its Recothrom and Preveleak hemostat and sealant products for approximately $153 million up front with a potential for contingent payments in the future. Mallinckrodt’s Recothorm is a stand-alone recombinant thrombin-based product with indications as an aid to hemostasis to control oozing blood and minor […]
Mallinckrodt beats Q2 earnings, misses on revenue
Shares in Mallinckrodt Pharmaceuticals (NYSE:MNK) fell today after the company beat earnings estimates but missed on revenue with its second quarter results. The U.K.-based company posted profits of $62.8 million, or 72¢ per share, on sales of $824.5 million for the 3 months ended June 30, for bottom-line loss of -68% on sales loss of -5% compared […]
DOJ subpoenas Mallinckrodt over opioids
Mallinckrodt Pharmaceuticals (NYSE:MNK) said yesterday that it received a subpoena from the U.S. Dept. of Justice requesting information related to its marketing practices and sales of opioids. The company, which manufactures only generic and non-promoted branded opioids, said that it has worked to prevent misuse and diversion of its products, pointing to efforts like its testimonies […]
Mallinckrodt enrolls first infant in registry for inhaled nitric oxide gas
Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that it included the first patient in its Phase IV registry evaluating the use of inhaled Inomax nitric oxide gas for premature neonates compared to term and near-term newborns. Inomax, which has FDA approval, is designed to boost oxygenation and lessen the need for extracorporeal membrane oxygenation in term and near-term […]
FDA grants regenerative medicine advanced therapy status to Mallinckrodt’s StrataGraft
Mallinckrodt Pharmaceuticals (NYSE:MNK) said today that its StrataGraft regenerative skin tissue won regenerative medicine advanced therapy status from the FDA. The tissue-based therapy is among the first products to be granted the designation. The 21st Century Cures Act, which was passed in 2016, enabled the FDA to give accelerated review approval to products that meet RMAT criteria. […]